LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $61,564 | -45.3% | 52,172 | -34.7% | 0.00% | – |
Q2 2023 | $112,601 | +179.1% | 79,859 | +196.9% | 0.00% | – |
Q1 2023 | $40,345 | +27.9% | 26,896 | -0.2% | 0.00% | – |
Q4 2022 | $31,532 | +425.5% | 26,950 | +389.4% | 0.00% | – |
Q3 2022 | $6,000 | -53.8% | 5,507 | -35.2% | 0.00% | – |
Q2 2022 | $13,000 | -95.8% | 8,505 | -95.8% | 0.00% | – |
Q1 2022 | $312,000 | -75.7% | 203,010 | -61.3% | 0.00% | – |
Q4 2021 | $1,286,000 | -27.6% | 524,841 | -25.5% | 0.00% | – |
Q3 2021 | $1,776,000 | +5820.0% | 704,444 | +6581.6% | 0.00% | – |
Q2 2021 | $30,000 | +36.4% | 10,543 | +9.4% | 0.00% | – |
Q1 2021 | $22,000 | -90.5% | 9,633 | -92.7% | 0.00% | – |
Q4 2020 | $231,000 | +90.9% | 131,322 | +1.6% | 0.00% | – |
Q3 2020 | $121,000 | -10.4% | 129,236 | -16.7% | 0.00% | – |
Q2 2020 | $135,000 | -45.8% | 155,101 | -48.4% | 0.00% | – |
Q1 2020 | $249,000 | +53.7% | 300,371 | +65.1% | 0.00% | – |
Q4 2019 | $162,000 | +224.0% | 181,953 | +258.1% | 0.00% | – |
Q3 2019 | $50,000 | – | 50,806 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Defender Capital, LLC. | 4,735,990 | $8,335,000 | 3.63% |
BROADWOOD CAPITAL INC | 34,005,379 | $59,849,000 | 3.55% |
Prescott General Partners LLC | 1,851,851 | $3,259,000 | 0.14% |
Strategic Wealth Investment Group, LLC | 66,917 | $118,000 | 0.07% |
Laidlaw Wealth Management LLC | 170,658 | $300,000 | 0.06% |
Humankind Investments LLC | 26,737 | $47,000 | 0.05% |
DAFNA Capital Management LLC | 80,000 | $141,000 | 0.04% |
Beirne Wealth Consulting Services, LLC | 45,000 | $79,000 | 0.04% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 680,839 | $1,198,000 | 0.02% |
Allegheny Financial Group LTD | 20,000 | $35,000 | 0.02% |